文献速递泌尿男性生殖肿瘤

帕博利珠单抗一线治疗晚期非透明细胞肾细胞癌的II期研究

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
PubMed 文献 · J Clin Oncol · 2021-02-02

KEYNOTE-427研究B队列评估帕博利珠单抗单药一线治疗晚期非透明细胞肾细胞癌的疗效与安全性。165例患者中客观缓解率为26.7%,中位缓解持续时间29.0个月,中位无进展生存期4.2个月,中位总生存期28.9个月。安全性与其他肿瘤类型相似。

要点

  • 帕博利珠单抗一线治疗晚期nccRCC的ORR为26.7%,中位DOR为29.0个月。
  • PD-L1 CPS≥1患者ORR为35.3%,CPS<1患者为12.1%。
  • 常见治疗相关不良事件为瘙痒(20.0%)和甲状腺功能减退(14.5%)。

核心结论

  • 一线帕博利珠单抗单药在非透明细胞肾细胞癌中显示出有前景的抗肿瘤活性。
  • 安全性特征与其他肿瘤类型中观察到的相似。

研究设计与样本

  • 开放标签、单臂、II期KEYNOTE-427研究B队列。
  • 纳入165例组织学确认、可测量、未接受过系统治疗的晚期非透明细胞肾细胞癌患者。
  • 帕博利珠单抗200 mg静脉注射每3周一次,最长24个月。
  • 主要终点为按RECIST v1.1评估的客观缓解率。

主要发现

  • 全部患者ORR为26.7%,中位缓解持续时间29.0个月,59.7%的缓解持续≥12个月。
  • PD-L1 CPS≥1和CPS<1患者的ORR分别为35.3%和12.1%。
  • 乳头状、嫌色细胞和未分类RCC的ORR分别为28.8%、9.5%和30.8%。
  • 中位无进展生存期4.2个月(95% CI 2.9-5.6),24个月无进展生存率18.6%。
  • 中位总生存期28.9个月(95% CI 24.3-未达到),24个月总生存率58.4%。

关键数值与推荐

  • 入组患者中71.5%为乳头状、12.7%为嫌色细胞、15.8%为未分类肾细胞癌。
  • 67.9%的患者为IMDC中危或高危,61.8%的患者PD-L1 CPS≥1。
  • 69.7%的患者报告治疗相关不良事件,最常见为瘙痒(20.0%)和甲状腺功能减退(14.5%)。
  • 2例治疗相关死亡(肺炎和心脏骤停)。

临床怎么用

  • 帕博利珠单抗单药可作为晚期非透明细胞肾细胞癌一线治疗的潜在选择。
  • PD-L1 CPS≥1患者可能从帕博利珠单抗治疗中获得更高缓解率。

局限性

  • 单臂设计,无对照,样本量有限。
  • 未按组织学亚型分层比较疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non-clear cell renal cell carcinoma (nccRCC). The phase II KEYNOTE-427 study (cohort B) was conducted to assess the efficacy and safety of single-agent pembrolizumab, a PD-1 inhibitor, in advanced nccRCC. METHODS: Patients with histologically confirmed, measurable (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) nccRCC and no prior systemic therapy received pembrolizumab 200 mg intravenously once every 3 weeks for ≤ 24 months. The primary end point was objective response rate (ORR) per RECIST v1.1. RESULTS: Among enrolled patients (N = 165), 71.5% had confirmed papillary, 12.7% had chromophobe, and 15.8% had unclassified RCC histology. Most patients (67.9%) had intermediate or poor International Metastatic RCC Database Consortium risk status and tumors with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 1 (61.8%). The median time from enrollment to database cutoff was 31.5 months (range, 22.7-38.8). In all patients, the ORR was 26.7%. The median duration of response was 29.0 months; 59.7% of responses lasted ≥ 12 months. The ORR by CPS ≥ 1 and CPS < 1 status was 35.3% and 12.1%, respectively. The ORR by histology was 28.8% for papillary, 9.5% for chromophobe, and 30.8% for unclassified. Overall, the median progression-free survival was 4.2 months (95% CI, 2.9 to 5.6); the 24-month rate was 18.6%. The median overall survival was 28.9 months (95% CI, 24.3 months to not reached); the 24-month rate was 58.4%. Overall, 69.7% of patients reported treatment-related adverse events, most commonly pruritus (20.0%) and hypothyroidism (14.5%). Two deaths were treatment related (pneumonitis and cardiac arrest). CONCLUSION: First-line pembrolizumab monotherapy showed promising antitumor activity in nccRCC. The safety profile was similar to that observed in other tumor types.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McDermott DF, Lee JL, Ziobro M, et al. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2021. PMID: 33529058. doi:10.1200/JCO.20.02365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。